It is a type of cancer that originates in the lymphatic system, which is part of the immune system. B cells are white blood cells that develop from bone marrow and make antibodies to fight infections. The lymphatic system is part of the circulatory system, which carries white blood cells t...
Some types of non-Hodgkin lymphoma grow and spread slowly and are called indolent. Others grow and spread quickly and are called aggressive. Treatment depends on the type and how far it has spread in your body. Chemotherapyis medicine used to treat cancer by killing tumor cells. Chemotherapy ...
Your doctor will only recommend watchful waiting if your disease is "indolent," which means that it's slow growing and not getting worse. To see if you're in that situation, they'll check your symptoms closely and look at the cancer cells under a microscope. ...
First, we saw approval of ipilimumab in melanoma, and then we saw the approval of pembrolizumab in melanoma and lung cancer. In 2015, we saw five approvals of single and combination therapies, and really the field is now exploding, as we saw here this year at ASCO. So, the data that ...
Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? The role of autologous hematopoietic cell transplantation (auto-HCT) in the management of indolent non-Hodgkin lymphomas (NHL) is shrouded in controversy. ... ...
the conclusion that there must be some overdiagnosis in CT screening’, he hedges ‘if the hypothesis of a sizable population of indolent lung tumors is correct, this is a fascinating phenomenon, given the very poor prognosis of symptomatic disease’. We believe that his scepticism is judicious....
Based on the degree of cellular and nuclear atypia, the lesions progress from PanIN-1 (low-grade dysplasia), which is probably indolent in nature and characterized by hyperplastic columnar ductal atypia, through PanIN-2 (moderate dysplasia) to PanIN-3 (carcinoma in situ), which shows high-...
Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour immunology and enabled the develop
Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour immunology and enabled the develop
description of patient and tumour characteristics can be a source of bias by prognostic factors, whose impact can be larger than the observed drug activity;- the natural history of malignant mesothelioma is often characterized by an indolent period where little objective disease progression is noted....